Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Health Systems
Economic Evaluations
Quality of Life
Lung Cancer Treatments and Mutations
Pharmaceutical Economics and Policy
Publication details
- Journal / source
- Therapeutic Innovation & Regulatory Science
- Volume
- 60
- Issue
- 4
- Pages
- 1084–1093
- Publication date
- 28 March 2026
- Language
- EN